Novo Nordisk
NVO
516 hedge funds and large institutions have $11.2B invested in Novo Nordisk in 2015 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 178 increasing their positions, 204 reducing their positions, and 29 closing their positions.
61% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $9.12M
55% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 29
2% more funds holding
Funds holding: 505 → 516 (+11)
5% more capital invested
Capital invested by funds: $10.7B → $11.2B (+$518M)
0.97% more ownership
Funds ownership: 18.96% → 19.92% (+0.97%)
3% less funds holding in top 10
Funds holding in top 10: 32 → 31 (-1)
13% less repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 204
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$180M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$127M |
| 3 |
WCM Investment Management
Laguna Beach,
California
|
+$114M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$79.4M |
| 5 |
State Farm Mutual Automobile Insurance
Bloomington,
Illinois
|
+$50.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$203M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$62.1M |
| 3 |
Renaissance Technologies
New York
|
-$24M |
| 4 |
Bank of New York Mellon
New York
|
-$22.5M |
| 5 |
CCM
Copeland Capital Management
Conshohocken,
Pennsylvania
|
-$21.4M |
NVO Hedge Fund Activity: Q2 2015 in Review
516 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2015, worth a combined $11.2B — up 4.8% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new NVO positions and 29 closed out — a net gain of 16 holders — while 178 added to existing stakes and 204 trimmed.
The largest buyer was Ameriprise, adding an estimated $180M. The largest seller was Jennison Associates, cutting an estimated $203M.
- 516 institutional investors held Novo Nordisk (NVO) as of Q2 2015, up from 505 in Q1 2015.
- Funds reported $11.2B of Novo Nordisk stock for Q2 2015, up 4.8% quarter-over-quarter.
- 45 funds opened new Novo Nordisk positions in Q2 2015 and 29 closed out, a net change of +16 holders.
- The largest Novo Nordisk buyer in Q2 2015 was Ameriprise, an estimated $180M added.
- The largest Novo Nordisk seller in Q2 2015 was Jennison Associates, an estimated $203M sold.
Based on aggregated 13F filings for Q2 2015.